Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 41

1.

Mouse Systems to Model Hepatitis C Virus Treatment and Associated Resistance.

Mesalam AA, Vercauteren K, Meuleman P.

Viruses. 2016 Jun 22;8(6). pii: E176. doi: 10.3390/v8060176. Review.

2.

Meta-Analysis of Combination Therapy of Chinese Herbs Plus Interferon and Ribavirin in Patients with Chronic Hepatitis C.

Wang J, Xin S, Jin X, Cheng Y, Yan T, Qing S, Ding N, Zhao P.

Med Sci Monit. 2016 May 30;22:1817-26.

3.

Treatment Response and Long-Term Outcome of Peginterferon α and Ribavirin Therapy in Korean Patients with Chronic Hepatitis C.

Jung CH, Um SH, Kim TH, Yim SY, Suh SJ, Yim HJ, Seo YS, Choi HS, Chun HJ.

Gut Liver. 2016 Sep 15;10(5):808-17. doi: 10.5009/gnl15360.

4.

Evaluation of Dual Therapy in Real Life Setting in Treatment-Naïve Turkish Patients with HCV Infection: A Multicenter, Retrospective Study.

Gürbüz Y, Tülek NE, Tütüncü EE, Koruk ST, Aygen B, Demirtürk N, Kınıklı S, Kaya A, Yıldırmak T, Süer K, Korkmaz F, Ural O, Akhan S, Günal Ö, Tuna N, Köse Ş, Gönen İ, Örmen B, Türker N, Saltoğlu N, Batırel A, Tuncer G, Bulut C, Sırmatel F, Ulçay A, Karagöz E, Tosun D, Şener A, Aynıoğlu A, Altunok ES.

Balkan Med J. 2016 Jan;33(1):18-26. doi: 10.5152/balkanmedj.2015.15859.

5.

Betulinic acid exerts anti-hepatitis C virus activity via the suppression of NF-κB- and MAPK-ERK1/2-mediated COX-2 expression.

Lin CK, Tseng CK, Chen KH, Wu SH, Liaw CC, Lee JC.

Br J Pharmacol. 2015 Jun 23. doi: 10.1111/bph.13233. [Epub ahead of print]

6.

Protein kinase expression as a predictive factor for interferon response in chronic hepatitis C patients.

Mohamed AA, Amin MA, Ragab MM, Ismail SA, Baki AA.

J Adv Res. 2014 Jan;5(1):117-23. doi: 10.1016/j.jare.2013.01.002.

7.

Sustained virological response to peginterferon therapy in patients infected with HCV (genotypes 2 and 3), with or without HIV.

Odolini S, Amadasi S, Cerini C, Giralda M, Nasta P, Castelli F.

BMC Infect Dis. 2014;14 Suppl 5:S4. doi: 10.1186/1471-2334-14-S5-S4.

8.

Erythropoietin rs1617640 G allele associates with an attenuated rise of serum erythropoietin and a marked decline of hemoglobin in hepatitis C patients undergoing antiviral therapy.

Amanzada A, Goralczyk AD, Reinhardt L, Moriconi F, Cameron S, Mihm S.

BMC Infect Dis. 2014 Sep 17;14:503. doi: 10.1186/1471-2334-14-503.

9.

Genotype 4 HCV infection is difficult to cure with pegylated interferon and ribavirin. Results from a Greek Nationwide Cohort Study.

Anagnostou O, Manolakopoulos S, Bakoyannis G, Papatheodoridis G, Zisouli A, Raptopoulou-Gigi M, Manesis E, Ketikoglou I, Dalekos G, Gogos C, Vassiliadis T, Tzourmakliotis D, Karatapanis S, Kanatakis S, Zoumpoulis -, Hounta A, Koutsounas S, Giannoulis G, Tassopoulos N, Touloumi G.

Hippokratia. 2014 Jan;18(1):57-64.

10.

Hepatitis C treatment & management.

Andronescu D, Diaconu S, Tiuca N, Purcarea RM, Andronescu CI.

J Med Life. 2014 Mar 15;7(1):31-6.

11.

SVR12 is higher than SVR24 in treatment-naïve hepatitis C genotype 1 patients treated with peginterferon plus ribavirin.

Thorlund K, Druyts E, Mills EJ.

Clin Epidemiol. 2014 Jan 15;6:49-58. doi: 10.2147/CLEP.S53302.

12.

Antiviral treatment of hepatitis C virus infection and factors affecting efficacy.

Zhu Y, Chen S.

World J Gastroenterol. 2013 Dec 21;19(47):8963-73. doi: 10.3748/wjg.v19.i47.8963. Review.

13.

A meta-analysis that compares the use of either peginterferon-α2a or peginterferon-α2b plus ribavirin for HCV infection.

Xiao N, Shi S, Zhuang H.

Hepat Med. 2010 Jul 28;2:99-109. Erratum in: Hepat Med. 2011;3(19):19.

14.

Cost-effectiveness analysis of adding low dose ribavirin to peginterferon alfa-2a for treatment of chronic hepatitis C infected thalassemia major patients in iran.

Mehrazmay A, Alavian SM, Moradi-Lakeh M, Mokhtari Payam M, Hashemi-Meshkini A, Behnava B, Miri SM, Karimi Elizee P, Tabatabaee SV, Keshvari M, Bagheri Lankarani K.

Hepat Mon. 2013 Sep 1;13(9):e10236. doi: 10.5812/hepatmon.10236.

15.
16.

Extended therapy duration for therapy-refractory hepatitis C patients with genotype 2.

Sato K, Yanagisawa M, Hashizume H, Yamazaki Y, Horiguchi N, Kakizaki S, Mori M.

World J Gastroenterol. 2013 Sep 14;19(34):5754-8. doi: 10.3748/wjg.v19.i34.5754.

17.

The Effect of Peginterferon Alpha-2a vs. Peginterferon Alpha-2b in Treatment of Naive Chronic HCV Genotype-4 Patients: A Single Centre Egyptian Study.

El Raziky M, Fathalah WF, El-Akel WA, Salama A, Esmat G, Mabrouk M, Salama RM, Khatab HM.

Hepat Mon. 2013 May 28;13(5):e10069. doi: 10.5812/hepatmon.10069.

18.

Alanine aminotransferase elevation during peginterferon alpha-2a or alpha-2b plus ribavirin treatment.

Nakamura M, Kanda T, Miyamura T, Wu S, Nakamoto S, Yokosuka O.

Int J Med Sci. 2013 Jun 15;10(8):1015-21. doi: 10.7150/ijms.6402.

19.
20.
Items per page

Supplemental Content

Support Center